Skip to main content
Log in

Costs of Diabetes

A Methodological Analysis of the Literature

  • Original Research Article
  • COI Studies in Diabetes
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective: To review studies on the costs of diabetes and its complications through a scheme designed specifically for assessing the quality of cost-of-illness (COI) studies.

Design and Setting: The methodology of COI studies in diabetes was analysed in order to assess the significance of quantitative results. The scheme adopted 7 items identified as the main points for discussing the methodological choices governing the results. We also used a checklist based on questions related to the 7 items.

Main outcome measures and results: The answers showed that many studies appear not to give technical details, so it is hard to understand themethod.Methodological choices varied widely between the studies. This is probably due to the lack of consensus on the methodology of COI studies. Based on the findings of this review, we suggest also some specific points that could help produce more reliable results on the costs of diabetes.

Conclusions: Clearly, a general consensus on COI studies is still remote, making the value of any comparison of results questionable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jefferson T, Demicheli V, Mugford M. Elementary economic evaluation in health care. London: BMJ Publishing Group, 1996

    Google Scholar 

  2. Zimmet P, McCarty D. The NIDDM epidemic: global estimates and projections; a look into the crystal ball. IDF Bull 1995; 40 (3): 8–16

    Google Scholar 

  3. World Health Organization (WHO). Prevention of diabetes mellitus. Geneva: WHO, 1994. Technical report series no.: 844

    Google Scholar 

  4. Alexander WD, South East Thames Diabetes Physicians Group. Diabetes care in a UK health region: activity, facilities and costs. Diabet Med 1988; 5: 577–581

    CAS  Google Scholar 

  5. Bransom ED. Financing the care of diabetesmellitus in the U.S. Diabetes Care 1992; 15 Suppl. 1: 1–5

    Google Scholar 

  6. Bransome ED. Improving the financing of diabetes care in the 1990s. Diabetes Care 1992; 15 Suppl. 1: 66–72

    PubMed  Google Scholar 

  7. Casparie AF, van der Waal MAE. Differences in preferences between diabetic patients and diabetologists regarding quality of care: a matter of continuity and efficiency of care? Diabet Med 1995; 12: 828–32

    Article  PubMed  CAS  Google Scholar 

  8. Currie CJ, Williams DRR, Peters JR. Patterns of in and out-patient activity for diabetes: a district survey. Diabet Med 1996; 13: 273–80

    Article  PubMed  CAS  Google Scholar 

  9. Damsgaard EM, Froland A, Green A. Use of hospital services by elderly diabetics: the Frederica study of diabetic and fasting hyperglycaemic patients aged 60-74 years. Diabet Med 1987; 4: 317–22

    Article  PubMed  CAS  Google Scholar 

  10. Gagliardino JJ, Olivera EM, Barragàn, et al. A simple economic evaluation model for selecting diabetes health care strategies. Diabet Med 1993; 10: 351–4

    Article  PubMed  CAS  Google Scholar 

  11. Geffner DL. Diabetes care in health maintenance organizations. Diabetes Care 1992; 15 Suppl. 1: 44–50

    PubMed  Google Scholar 

  12. Glasgow RE. A practical model of diabetes management and education. Diabetes Care 1995; 18 (1): 117–26

    Article  PubMed  CAS  Google Scholar 

  13. Korn AM. Case management and quality of care for diabetic patients. Diabetes Care 1992; 15 Suppl. 1: 59–61

    PubMed  Google Scholar 

  14. Leese B. Diabetes mellitus and the St Vincent declaration: the economic implications. Pharmacoeconomics 1995; 7 (4): 292–307

    Article  PubMed  CAS  Google Scholar 

  15. McGill M. Diabetes ambulatory care: its impact in the approach and cost of treating people with diabetes. IDF Bull 1995; 40 (4): 29–35

    Google Scholar 

  16. Olsson J, Persson U, Tollin C, et al. Comparison of excess costs of care and production losses because of morbidity in diabetic patients. Diabetes Care 1994; 17 (11): 1257–63

    Article  PubMed  CAS  Google Scholar 

  17. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996; 276 (17): 1409–15

    Article  Google Scholar 

  18. The Diabetes Control and Complications Trial Research Group. Resource utilization and costs of care in the diabetes control and complications trial. Diabetes Care 1995; 18 (11): 1468–78

    Article  Google Scholar 

  19. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications, 1987

    Google Scholar 

  20. Drummond MF, Davies LM, Ferris FL. Assessing the costs and benefits of medical research: the diabetic retinopathy study. Soc Sci Med 1992; 34 (9): 973–81

    Article  PubMed  CAS  Google Scholar 

  21. Dasbach EJ, Fryback DG, Newcomb PA, et al. Cost-effectiveness of strategies for detecting diabetic retinopathy. Med Care 1991; 29 (1): 20–39

    Article  PubMed  CAS  Google Scholar 

  22. Frendrick A, Javitt JC and Chiang YP. Cost effectiveness of the screening and treatment of diabetic retinopathy: what are the costs of underutilization? Int J Technol Assess Health Care 1992; 8: 694–707

    Article  Google Scholar 

  23. Javitt JC, Aiello LP. Cost effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996; 124: 164–9

    PubMed  CAS  Google Scholar 

  24. Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type 1 diabetics. Ophthalmology 1989; 96 (2): 255–64

    PubMed  CAS  Google Scholar 

  25. Lairson DR, Pugh JA, Kapadia AS, et al. Cost effectiveness of alternative methods for diabetic retinopathy screening. Diabetes Care 1992; 15: 1369–77

    Article  PubMed  CAS  Google Scholar 

  26. Savolainen EA, Lee QP. Diabetic retinopathy. Need and demand for photocoagulation and its cost effectiveness: evaluation based on services in the UK. Diabetologia 1982; 23: 138–40

    CAS  Google Scholar 

  27. Schulper MJ, Buxton MJ, Ferguson BA, et al. A relative cost effectiveness analysis of different methods of screening for diabetic retinopathy. Diabet Med 1991; 8: 644–50

    Article  Google Scholar 

  28. Schulper MJ, Buxton MJ, Ferguson BA, et al. Screening for diabetic retinopathy: a relative cost effectiveness analysis of altrenative modalities and strategies. Health Econ 1992; 1: 39–51

    Article  Google Scholar 

  29. Vondeling H. Evaluation of argon laser treatment of diabetic retinopathy and its diffusion in theNetherlands. Health Policy 1993; 23: 97–111

    Article  PubMed  CAS  Google Scholar 

  30. Garattini L, Brunetti M, Salvioni F, et al. Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy. Pharmacoeconomics 1997; 12 (1): 67–75

    Article  PubMed  CAS  Google Scholar 

  31. Borch-Johnsen K, Wentzel H, Viberti GC, et al. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes. BMJ 1993; 306: 1722–5

    Article  PubMed  CAS  Google Scholar 

  32. Kiber BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 1995; 311: 1595–9

    Article  Google Scholar 

  33. Le Floch JP, Charles MA, Philippon C, et al. Cost effectiveness of screening for microalbuminuria using immunochemical dipstick tests or laboratory assays in diabetic patients. Diabet Med 1994; 11: 349–56

    Article  PubMed  Google Scholar 

  34. Rodby RA, Lewis EJ, Firth LM. An economic analysis of ET in the treatment of diabetic nephropathy. Diabetes Care 1996; 19 (10): 1051–61

    Article  PubMed  CAS  Google Scholar 

  35. Siegel JE, Krolewski AS, Warram JH, et al. Cost effectiveness of screening and early treatment of nephropathy in patients with IDDM. J Am Soc Nephrol 1992; 3: 3111–9

    Google Scholar 

  36. Eckman MH, Greenfield S, Mackey WC, et al. Foot infections in diabetic patients: decision and cost-effectiveness analysis. JAMA 1995; 237 (9): 712–20

    Article  Google Scholar 

  37. Benton GS, Kerstein MD. Cost effectiveness of early digit amputation in the patient with diabetes. Surg Gynecol Obstet 1985; 161: 523–4

    PubMed  CAS  Google Scholar 

  38. Songer T. The economic costs of NIDDM. Diabetes Metab Rev 1992; 8 (4): 389–404

    Article  PubMed  CAS  Google Scholar 

  39. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992; 2 (1): 1–4

    Article  PubMed  CAS  Google Scholar 

  40. Mooney G. Key issues in health economics. London: Harvester Wheatsheaf, 1994

    Google Scholar 

  41. Davey PJ, Leeder SR. The cost of migraine: more than just a headache? Pharmacoeconomics 1992; 2 (1): 5–7

    Article  PubMed  CAS  Google Scholar 

  42. Simell TT, Sintonen H, Hahl J, et al. Costs of insulin dependent diabetes mellitus. Pharmacoeconomics 1996; 9 (1): 24–38

    Article  PubMed  CAS  Google Scholar 

  43. Rice DP. Cost of illness studies: fact or fiction? Lancet 1994; 344: 1519–20

    Article  PubMed  CAS  Google Scholar 

  44. McMaster Health Sciences Centre. How to read clinical journals. VII: to understand an economic evaluation (parts A and B). Can Med Assoc J 1984; 130: 1156–434

    Google Scholar 

  45. Gerard K. Cost-utility in practice: a policy maker’s guide to the state of the art. Health Policy 1992, 21: 249–79

    Article  PubMed  CAS  Google Scholar 

  46. Australian Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian Governement Publishing Service, 1995

    Google Scholar 

  47. Canadian Coordinating Office on Health Tecnology Assessment (CCOHTA): Guidelines for economic evaluations of pharmaceutical: Canada. 1st ed. Ottawa (ON): CCOHTA, 1994

    Google Scholar 

  48. Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto (ON): Ontario Ministry of Health, 1994

    Google Scholar 

  49. England and Wales Department of Health. Guidelines on good practice in the conduct of economic evaluation of medicines. London: Department of Health, 1994

    Google Scholar 

  50. Ament A, Evers S. Cost of illness studies in health care: a comparison of two cases. Health Policy 1993; 26: 29–42

    Article  PubMed  CAS  Google Scholar 

  51. Sheldon T. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1–11

    Article  PubMed  CAS  Google Scholar 

  52. Buxton M, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217–27

    Article  PubMed  CAS  Google Scholar 

  53. Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997

    Google Scholar 

  54. Blumenschein K, Johannesson M. Economic evaluation in healthcare. Pharmacoeconomics 1996; 10 (2): 114–22

    Article  PubMed  CAS  Google Scholar 

  55. Koopmanschap MA, Rutten FFH. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics 1993; 4 (6): 446–54

    Article  PubMed  CAS  Google Scholar 

  56. Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10 (5): 460–6

    Article  PubMed  CAS  Google Scholar 

  57. Rice DP. Estimating the cost of illness. Health economic series No.6: public health service. Washington, DC: US Government Printing Office, 1966

    Google Scholar 

  58. Tediosi F, Pagano E, Garattini L. Costi della schizofrenia: un’-analisi metodologica della letteratura esistente. Soc Ital Psichiatria: Boll Sci Inform 1998; Anno V, Marzo.-Luglio: 41–7

    Google Scholar 

  59. Tolpin HG, Bentkover JD. Economic costs of illness: decision making applications and practical considerations. In: Scheffler R, Rossiter L, editors. Advances in health economic and health services resources. Greenwich (CT): JAI Press, 1983

    Google Scholar 

  60. Bootman JL, Townsend RJ, McGhan WF. Principles of pharmacoeconomics. Cincinnati (OH): Harvey Whitney Books Company, 1991

    Google Scholar 

  61. Weisbrod B. Economics of public health. Philadelphia (PA): University of Pennsylvania Press, 1961

    Google Scholar 

  62. Cooper BS, Rice DP. The economic cost of illness revisited. Soc Security Bull 1976; 39: 21–36

    CAS  Google Scholar 

  63. Koopmanschap MA, Rutten FFH, van Ineveld MB, et al. The friction cost method for measuring indirect costs of disease. Health Econ 1995; 14: 171–89

    Article  CAS  Google Scholar 

  64. Agro KE, Bradley CA, Mittmann N, et al. Sensitivity analysis in health economic and pharmacoeconomic studies. Pharmacoeconomics 1997; 11 (1): 75–88

    Article  PubMed  CAS  Google Scholar 

  65. Leese B. The cost of diabetes and its complications: a review. Centre for health economics. York: University of York, 1991

    Google Scholar 

  66. Jönsson B. Diabetes-the cost of illness and the cost of control. Acta Med Scand Suppl 1983; 671: 19–27

    PubMed  Google Scholar 

  67. Gerard K, Donaldson C, Maynard AK. The cost of diabetes. Diabet Med 1989; 6: 164–70

    Article  PubMed  CAS  Google Scholar 

  68. American Diabetes Association (ADA). Direct and indirect costs of diabetes in the United States, 1992. Alexandria: ADA Inc., 1993

    Google Scholar 

  69. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus in 1992. J Clin Endocrinol Metab 1994; 78 (4): 809A–F

    Article  PubMed  CAS  Google Scholar 

  70. Phillips M, Salmeron J. Diabetes inMexico: a serious and growing problem. World Health Stat Q 1992; 45: 338–46

    PubMed  CAS  Google Scholar 

  71. Kegler MC, Lengerich EJ, Norman M, et al. The burden of diabetes in North Carolina. North Carolina Med J 1995; 56: 141–4

    CAS  Google Scholar 

  72. Warner DC, McCandless RR, De Nino LA, et al. Costs of diabetes in Texas, 1992. Diabetes Care 1996; 19 (12): 1416–9

    Article  PubMed  CAS  Google Scholar 

  73. Kangas T, Aro S, Koivisto VA, et al. Structure and costs of health care of diabetic patients in Finland. Diabetes Care 1993; 19 (5): 494–7

    Article  Google Scholar 

  74. McKendry JBR. Direct costs of diabetes care: a survey in Ottawa, Ontario 1986. Can J Public Health 1989; 80: 124–8

    PubMed  CAS  Google Scholar 

  75. Triomphe A, Flori YA, Costagliola D, et al. The cost of diabetes in France. Health Policy 1988; 9: 39–48

    Article  PubMed  CAS  Google Scholar 

  76. Chale SS, Swai ABM, Mujinja PGM, et al. Must diabetes be a fatal disease in Africa? Study of costs of treatment. BMJ 1992; 304: 1215–8

    CAS  Google Scholar 

  77. Gray A, Fenn P, McGuire A. The cost of insulin-dependent diabetes mellitus (IDDM) in England andWales. Diabet Med 1995; 12: 1068–76

    Article  PubMed  CAS  Google Scholar 

  78. Stern Z, Levy R. The direct cost of type 1 diabetes mellitus in Israel. Diabet Med 1994; 11: 528–33

    Article  PubMed  CAS  Google Scholar 

  79. Huse DM, Oster G, Killen AR, et al. The economic costs of non-insulin-dependent diabetes mellitus. JAMA 1989; 262 (19): 2708–13

    Article  PubMed  CAS  Google Scholar 

  80. Hart WM, Espinosa C, Rovira J. Asimulation model of the cost of the incidence of IDDM in Spain. Diabetologia 1997; 40: 312–8

    Article  Google Scholar 

  81. Maynard A. Economic evaluation techniques in healthcare: reinventing the wheel? Pharmacoeconomics 1997; 11 (2): 115–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Livio Garattini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pagano, E., Brunetti, M., Tediosi, F. et al. Costs of Diabetes. Pharmacoeconomics 15, 583–595 (1999). https://doi.org/10.2165/00019053-199915060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199915060-00006

Keywords

Navigation